文献速递胸部病理细胞病理与分子病理

非小细胞肺癌PD-L1表达:细胞学、小活检与手术切除标本的比较

PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
PubMed 文献 · Cancer Cytopathol · 2017-10-12

本研究评估用细胞学标本量化非小细胞肺癌PD-L1表达的可行性,并与小活检和手术切除标本比较。采用22C3 pharmDx免疫组化检测,以≥50%存活肿瘤细胞着色为阳性,要求≥100个肿瘤细胞。214份标本中206份(96%)细胞量充足,细胞学阳性率与组织学无显著差异,配对的23例中21例(91%)结果一致。

要点

  • 细胞学标本可量化PD-L1表达,结果与手术切除和小活检标本相当。
  • 细胞学标本细胞量充足率为90%(36/40),小活检为96%(69/72)。
  • 配对的23例患者中21例(91%)PD-L1结果一致。

核心结论

  • 细胞学标本可量化PD-L1表达,结果与小活检和手术切除标本相当,包括在配对标本中。

研究设计与样本

  • 从188例患者收集214份标本,用22C3 pharmDx免疫组化量化PD-L1表达,细胞学标本在细胞块切片上进行检测。

主要发现

  • 214份标本中206份(96%)细胞量充足,包括细胞学36/40(90%)和小活检69/72(96%)。
  • 小活检与手术切除标本PD-L1免疫组化可行性无显著差异(P = .99)。
  • 细胞学与组织学标本PD-L1阳性百分比无显著差异(P = .083)。
  • 23例收集了>1份标本的患者中21例(91%)PD-L1表达一致。
  • 年龄、性别、诊断和标本部位间PD-L1阳性率无显著差异。

关键数值与推荐

  • PD-L1阳性定义为≥50%存活肿瘤细胞着色,检测 adequacy 要求≥100个肿瘤细胞。

临床怎么用

  • 细胞学标本(细胞块切片)可用于PD-L1免疫组化检测,结果与组织学标本可比,支持在细胞学标本上开展该检测。

局限性

  • 未来需研究其他抗体及预测免疫治疗反应的能力;原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: One immunotherapeutic agent for patients with advanced non-small cell lung carcinoma, pembrolizumab, has a companion immunohistochemistry (IHC)-based assay that predicts response by quantifying programmed death-ligand 1 (PD-L1) expression. The current study assessed the feasibility of quantifying PD-L1 expression using cytologic non-small cell lung carcinoma specimens and compared the results with those from small biopsy and surgical resection specimens. METHODS: PD-L1 expression was quantified using the IHC-based 22C3 pharmDx assay, with "positivity" defined as staining in ≥50% viable tumor cells; ≥ 100 tumor cells were required for test adequacy. For cytology specimens, IHC was performed on cell block sections. RESULTS: A total of 214 specimens were collected from 188 patients, 206 of which (96%) were found to be adequately cellular, including 36 of 40 cytology (90%) and 69 of 72 small biopsy (96%) specimens. There was no significant difference noted with regard to the feasibility of PD-L1 IHC on small biopsy specimens compared with surgical resection specimens (P = .99), or between the percentage of PD-L1-positive cytology and histology (including surgical resection and histologic small biopsy) specimens (P = .083). PD-L1 expression was found to be concordant among samples from 21 of 23 patients from whom > 1 specimen was collected (91%). There also was no significant difference observed with regard to rates of PD-L1 positivity when comparing age, sex, diagnosis, and specimen site. CONCLUSIONS: Quantification of PD-L1 expression is feasible on cytology specimens, and the results are comparable to those obtained from surgical resection and small biopsy specimens, including in matched specimens and using a single predictive IHC marker. Future studies will be necessary to determine the comparative value of other antibodies and their ability to predict response to immunotherapy. Cancer Cytopathol 2017;125:896-907. © 2017 American Cancer Society.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Heymann JJ, Bulman WA, Swinarski D, et al. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens. Cancer Cytopathol. 2017. PMID: 29024471. doi:10.1002/cncy.21937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。